Formulation and Evaluation of Bilayer Tablet of Atorvastain Calcium (Immediate Release) and Nifedipine (Sustained Release)
Cardiovascular diseases remain a major cause of morbidity and mortality worldwide, with hypertension and dyslipidemia frequently occurring together and significantly increasing cardiovascular risk. Long-term management of these conditions often requires multiple medications, leading to increased pill burden and reduced patient compliance. The present study aimed to formulate and evaluate a bilayer tablet comprising an immediaterelease (IR) layer of Atorvastatin Calcium and a sustained-release (SR) layer of Nifedipine to provide combined therapeutic benefits in a single dosage form. Preformulation studies, including organoleptic evaluation, solubility studies, calibration curve preparation, and drug–excipient compatibility studies using FTIR and DSC, were performed. The immediate-release layer of Atorvastatin Calcium was formulated using suitable superdisintegrants to achieve rapid drug release, whereas the sustained-release layer of Nifedipine was developed using HPMC K100M as a release-retarding polymer to prolong drug release. Bilayer tablets were prepared by the direct compression technique and evaluated for pre-compression parameters such as angle of repose, bulk density, tapped density, Carr’s index, and Hausner ratio. Post-compression evaluation included hardness, thickness, weight variation, friability, drug content uniformity, and in vitro dissolution studies. The prepared formulations exhibited satisfactory flow properties and acceptable physicochemical characteristics. The immediate-release layer demonstrated rapid drug release, while the sustained-release layer provided prolonged release of Nifedipine over the desired period. Drug release kinetics indicated diffusion-controlled release from the sustained-release matrix. The optimized formulation showed satisfactory tablet integrity and performance characteristics. The study demonstrates that bilayer tablet technology can successfully combine immediate and sustained drug release profiles within a single dosage form. Such a formulation has the potential to improve patient compliance, reduce dosing frequency, and provide effective management of patients suffering from concurrent hypertension and dyslipidemia.
Authors
- Manish S. Junagade
- Sakshi Sanjay Pawar
- Miss Mustabshira Arif Shaikh
- Roshan Balu Nirbhavane
- Satyajeet Vishnu Panpatil
Publication Details
- Journal
- International Journal of Drug Delivery Technology
- Published
- 2026-11-16
- DOI
- https://doi.org/10.25258/ijddt.16.80s.91
- Primary Topic
- Drug Solubulity and Delivery Systems
- Type
- article
- Field-Weighted Citation Impact
- 0.00